Supreme Court Narrows Induced-Infringement Theory Based on Product Communications

7.1.26

Issued June 4, 2026, the Supreme Court’s decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. clarifies what a patent owner must plead to state a claim for induced infringement under 35 U.S.C. § 271(b). The key point is defendant-focused: liability requires affirmative conduct by the accused inducer that actively encourages infringement. Product capability, ordinary commercial statements, omissions, and customer inference generally are not enough.

Background

Amarin markets Vascepa, which the FDA first approved to treat severe hypertriglyceridemia and later approved for reducing cardiovascular risk in certain statin-treated patients. Amarin held method-of-use patents covering the later cardiovascular-risk indication.

Hikma sought approval to sell generic icosapent ethyl using a “skinny label” that included only the unpatented indication and carved out the patented cardiovascular-risk use. Amarin sued, alleging that Hikma’s label, patient leaflet, website, and press releases induced physicians and pharmacists to infringe.

The district court dismissed the claim. The Federal Circuit reversed, reasoning that the materials could plausibly be read as encouraging infringement. The Supreme Court reversed.

Holding

The Court reaffirmed that induced infringement requires (i) direct infringement by another, (ii) knowledge that the induced acts constitute infringement, and (iii) active steps by the defendant to encourage infringement. The third element controlled.

The Court rejected the Federal Circuit’s framing. The question is not whether a physician could interpret the accused materials as encouraging infringement. The question is whether Hikma itself took affirmative steps that actively encouraged the patented use. Inducement may be express or implicit, but it must be clear and affirmative.

Why Hikma Prevailed

The Court found that Hikma’s communications described the product and its availability but did not encourage customers to practice the patented method. The Court emphasized that ordinary commercial statements, routine product information, and legally required disclosures do not become inducement merely because a customer might use the product in an infringing way. Likewise, silence, omissions, and generalized statements cannot substitute for evidence that the accused company affirmatively encouraged the patented use.

Why It Matters

Although the case arose from pharmaceutical labeling, the reasoning may apply more broadly to products with infringing and non-infringing uses. Software platforms, AI tools, medical devices, electronics, industrial equipment, technical manuals, training materials, support scripts, and product webpages may all be relevant in inducement disputes.

The decision strengthens the distinction between describing a product and teaching customers to use it in an infringing way. That distinction should guide patent enforcement strategy and review of customer-facing communications.

For patent owners, Hikma underscores the need to plead affirmative conduct by the accused party, not merely customer inference; the strongest allegations will identify instructions, examples, training, support responses, sales scripts, demo materials, or technical documentation that teach the patented method.

For companies facing inducement risk, the decision reinforces the value of reviewing manuals, FAQs, webpages, release notes, examples, and support scripts for language that could be read as teaching a patented workflow, and of tying product statements to lawful, licensed, or non-infringing uses when patent risk is known.

Bottom Line

Hikma does not eliminate induced-infringement liability. It narrows theories built on ambiguity, omission, or ordinary product communications. The focus remains on whether the accused party clearly and affirmatively encouraged infringing use.

Sam Raque | Associate Attorney